Summary
- The Delhi High Court has set aside the Controller of Patents' refusal of Array BioPharma Inc.'s combination patent application in a significant ruling.
- The Court found that the Controller incorrectly applied Section 3(d) regarding the inventive step and patentability criteria.
- This decision remands the case for fresh consideration, potentially impacting future combination patent applications.
- The ruling emphasizes the importance of correctly assessing inventive steps in patent law, which could reshape industry practices.
Join the discussion — sign up to comment, upvote, and save articles.